Benitec Biopharma Inc 2025年度报告

For the fiscal year endedJune 30, 2025 Transition Report under Section13 or 15(d) of the Securities Exchange Act of 1934 Benitec Biopharma Inc.(Exact name of registrant as specified in its charter) Registrant’s telephone number, including area code(510)780-0819 Securities registered pursuant to Section12(b) of the Act: Title of each classTradingSymbol(s)Name of each exchangeon which registeredCommon Stock, par value $0.0001BNTCThe Nasdaq Stock Market LLC None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section13 or 15(d) of the Act.Yes☐No☒ Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. LargeAcceleratedFiler☐Non-Accelerated Filer☒ Accelerated Filer☐SmallerReportingCompany☒Emerging Growth Company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes☐No☒ The aggregate market value of the Registrant’s common equity held by non-affiliates, based upon the closing price of the Registrant’s securities on theNasdaq Capital Market of $12.63 on December31, 2024 was approximately $152,964,292 There were26,250,469shares of the Registrant’s common stock, $0.0001 par value per share, outstanding on September17, 2025. EXPLANATORY NOTE Benitec Biopharma Inc. is filing this Amendment No.1 (this “Form 10-K/A”) to its Annual Report on Form 10-K for the fiscal year ended June30, 2025(the “Original 10-K”), as originally filed with the Securities and Exchange Commission (the “Commission”) on September22, 2025, for the purpose ofincluding the conformed signature of Baker Tilly US, LLP on the Report of Independent Registered Public Accounting Firm (the “Report”) within Item8 of the Original 10-K. The conformed signature was inadvertently omitted from the version of the Report that was filed with the Original 10-K. ThisForm 10-K/A includes the Report with the conformed signature. The exhibit list appearing in Item 15 of the Form 10-K has been updated to indicate thatExhibits 21.1 and 97 were previously filed. This Form 10-K/A includes new certifications, as required by Rule 12b-15 under the Securities ExchangeAct of 1934, from our Chief Executive Officer and Chief Financial Officer, dated as of the date of filing of this Form 10-K/A, and a new Consent ofIndependent Registered Public Accounting Firm, dated as of the date of filing of this Form 10-K/A. Except for the correction described above, this Form 10-K/A does not purport to update any disclosures contained in the annual report. For disclosuressubsequent to September22, 2025, please see the Company’s reports filed with the Commission after that date. Item 8. Financial Statements and Supplementary Data. BENITEC BIOPHARMA INC.INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Report of Independent Registered Public Accounting FirmBaker Tilly(PCAOB Firm ID No.23)F-2Consolidated Balance SheetsF-3Consolidated Statements of Operations and Comprehensive LossF-4Consolidated Statements of Stockholders’ EquityF-5Consolidated Statements of Cash FlowsF-6Notes to Consolidated Financial StatementsF-7 Table of